AtaiBeckley

Executive Summary

AtaiBeckley, formed in 2025 through the merger of atai Life Sciences and Beckley Psytech, is a German biotech leader developing rapid-acting, durable psychedelic therapies for difficult-to-treat mental health conditions. The company combines atai's broad drug development platform with Beckley's specialized expertise in low-dose psychedelics, aiming to transform outcomes in depression, anxiety, and addiction. With a focus on patient-first science, AtaiBeckley is advancing a pipeline of novel compounds, including BPL-003 (intranasal 5-MeO-DMT) and VLS-01 (oral DMT), targeting major depressive disorder and treatment-resistant depression. The company has raised significant capital and benefits from a strong scientific advisory board, positioning it as a frontrunner in the psychedelic renaissance. While regulatory and clinical risks remain, the unmet need in mental health and promising early data support a favorable outlook.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b topline data for BPL-003 in treatment-resistant depression65% success
• Q4 2026Initiation of Phase 3 trial for VLS-01 in major depressive disorder70% success
• Q2 2026FDA breakthrough therapy designation for low-dose psilocybin in anxiety disorders50% success